The addition of PD-1 inhibitors to CT represents a major therapeutic development for advanced or metastatic 1L ESCC, as treatment was previously only with CT regimens with limited survival benefits (41, 47). The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.